Free Submission Public Relations &
Deutsch English


PharmaPoint: Hemophilia A and B - Italy Drug Forecast and Market Analysis to 2022 - New Market Study Published

Print article Print article
2014-01-23 21:02:50 - New Pharmaceuticals market report from GlobalData: "PharmaPoint: Hemophilia A and B - Italy Drug Forecast and Market Analysis to 2022"

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

As in other 5EU countries, the high cost of recombinant prophylaxis therapy is of great concern among Italian physicians and the desire among regulators to

contain the annual cost of hemophilia care will be a barrier to stronger growth in the market. However, GlobalData believes that the clinical benefit offered by the long-acting rFVIII and rFIX products will be sufficient to allow companies to obtain a small premium price point for their new products in the Italian marketplace.

Full Report Details at
- ..


* Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in Italy from 2012-2022.
* Analysis of the impact of key events as well the drivers and restraints affecting Italy Hemophilia A and B market.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2012-2022 in Italy

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis and Quality of Life
3.2 Symptoms
3.2.1 Hemophilia A and B
3.2.2 Inhibitors
4 Disease Management
4.1 Treatment Overview
4.1.1 Hemophilia A and B Diagnosis
4.1.2 Hemophilia A and B Treatment
4.1.3 Inhibitors Diagnosis
4.1.4 Inhibitors Treatment
4.2 Italy
4.2.1 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitive Assessment
5.3 Product Profiles - Major Brands, Hemophilia A
5.3.1 Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free)
5.3.2 Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant))
5.3.3 Xyntha/ReFacto AF (moroctocog alfa; Antihemophilic Factor [Recombinant], Plasma/Albumin-Free)
5.3.4 Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free)
5.4 Product Profiles - Hemophilia B
5.4.1 BeneFIX (nonacog alfa; coagulation factor IX [recombinant])
5.5 Product Profiles - Hemophilia A and B with Inhibitors
5.5.1 NovoSeven RT (coagulation factor VIIa [recombinant])
6 Opportunity and Unmet Need
6.1 Overview
6.2 Opportunities Analysis
6.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections
6.2.2 Lower-Cost Recombinant Replacement Therapies
6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients
6.2.4 More Convenient Drug Administration
6.2.5 Oral Formulation of Recombinant Replacement Therapies
6.3 Unmet Needs Gap Analysis
6.3.1 Long-Acting FVIII Replacement Therapies
6.3.2 Gene Therapy Treatments for Hemophilia A and B
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development - Hemophilia A
7.2.1 Eloctate (rFVIII-Fc) (recombinant factor VIII fusion protein)
7.2.2 BAY 94-9027 (octocog alfa)
7.2.3 BAX-855
7.2.4 Novoeight (turoctocog alfa; NN7008)
7.2.5 N8-GP (NN7088)
7.2.6 CSL-627 (rFVIII-SC)
7.2.7 Hcl-rhFVIII
7.3 Promising Drugs in Clinical Development - Hemophilia B
7.3.1 Alprolix (rFIXFc)
7.3.2 CSL-654 (rIX-FP)
7.3.3 N9-GP (NN-7999)
7.3.4 IB1001 (trenacog alfa)
7.4 Promising Drugs in Clinical Development - Hemophilia A and B Patients with Inhibitors
7.4.1 BAX-817 (rFVIIa BI)
8 Market Outlook
8.1 Italy
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Hemophilia Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.6 About the Authors
9.6.1 Authors
9.6.2 Global Head of Healthcare
9.7 About GlobalData
9.8 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Symptoms of Hemophilia A and B

Full Table of Contents is available at:

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact